GSK plc GSK announced that the European Commission has granted approval for the expanded use of Jemperli (dostarlimab) plus ...

The green light means GSK has unlocked a niche for Jemperli (dostarlimab) that could help its quest to build the product into a $1 billion-plus blockbuster, although the label agreed with the FDA ...

GSK’s Jemperli is designed to help the body’s immune system find and attack cancer cells, and is already approved in the EU ...

GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug. The latest readout from the ...

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

The company noted that the label for Jemperli plus chemotherapy in the US was expanded to all adult patients with primary advanced or recurrent endometrial cancer in August 2024. For More Such ...

GSK’sGSK1.44%increase; green up pointing triangle cancer drug Jemperli cleared an important hurdle ahead of potentially expanding its European Union marketing permission, in a boost to the ...

GSK plc (GSK, GSK.L) announced the European Commission has approved Jemperli in combination with chemotherapy for first-line ...

In the first nine months of 2024, Jemperli recorded sales worth £318 million. Sales of the drug are being driven by new patient starts in the United States. Some label expansion studies are ...

The label for Jemperli plus chemotherapy in the U.S. was expanded to all adult patients with primary advanced or recurrent endometrial cancer in August 2024. Recently, GSK agreed to acquire IDRx ...